Back to Journals » Drug Design, Development and Therapy » Volume 10

Discovery of a novel anticancer agent with both anti-topoisomerase I and II activities in hepatocellular carcinoma SK-Hep-1 cells in vitro and in vivo: Cinnamomum verum component 2-methoxycinnamaldehyde

Authors Perng D, Tsai Y, Cherng J, Wang J, Chou K, Shih C, Cherng J

Received 2 August 2015

Accepted for publication 15 September 2015

Published 5 January 2016 Volume 2016:10 Pages 141—153


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Wei Duan

Daw-Shyong Perng,1 Yu-Hsin Tsai,2 Jonathan Cherng,3 Jeng-Shing Wang,4 Kuo-Shen Chou,5 Chia-Wen Shih,6 Jaw-Ming Cherng7

1Department of Gastroenterology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan, Republic of China; 2Sierra College, Rocklin, CA, USA; 3Faculty of Medicine, Medical University of Lublin, Lublin, Poland; 4Department of Internal Medicine, Antai Tian-Sheng Memorial Hospital, Pingtung, 5Department of Family Medicine, Saint Mary’s Hospital Luodong, 6Department of Pathology, Lotung Poh-Ai Hospital, 7Department of Internal Medicine, Saint Mary’s Hospital Luodong, Yilan, Taiwan, Republic of China

Abstract: Cinnamomum verum is used to make the spice cinnamon and has been used as a traditional Chinese herbal medicine for various applications. We evaluated the anticancer effect of 2-methoxycinnamaldehyde (2-MCA), a constituent of the bark of the plant, and its underlying molecular biomarkers associated with carcinogenesis in human hepatocellular carcinoma SK-Hep-1 cell line. The results show that 2-MCA suppressed proliferation and induced apoptosis as indicated by mitochondrial membrane potential loss, activation of caspase-3 and caspase-9, increase in the DNA content in sub-G1, and morphological characteristics of apoptosis, including blebbing of plasma membrane, nuclear condensation, fragmentation, apoptotic body formation, and long comet tail. In addition, 2-MCA also induced lysosomal vacuolation with increased volume of acidic compartments, suppressions of nuclear transcription factors NF-κB, cyclooxygenase-2, prostaglandin E2 (PGE2), and both topoisomerase I and II activities in a dose-dependent manner. Further study reveals the growth-inhibitory effect of 2-MCA was also evident in a nude mice model. Taken together, the data suggest that the growth-inhibitory effect of 2-MCA against SK-Hep-1 cells is accompanied by downregulations of NF-κB-binding activity, inflammatory responses involving cyclooxygenase-2 and PGE2, and proliferative control involving apoptosis, both topoisomerase I and II activities, together with an upregulation of lysosomal vacuolation and volume of acidic compartments. Similar effects (including all of the above-mentioned effects) were found in other tested cell lines, including human hepatocellular carcinoma Hep 3B, lung adenocarcinoma A549, squamous cell carcinoma NCI-H520, colorectal adenocarcinoma COLO 205, and T-lymphoblastic MOLT-3 (results not shown). Our data ­suggest that 2-MCA could be a potential agent for anticancer therapy.

Keywords: 2-methoxycinnamaldehyde, anticancer, SK-Hep-1 cells, topoisomerase I, topoisomerase II

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]